Novo Integrated Sciences (NVOS) Key Ratios
$0.00
$0.00 (0.00%)As on 01-Sep-2026 16:00EDT
Market cap
$0 Mln
Revenue (TTM)
$14 Mln
P/E Ratio
--
P/B Ratio
0
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -20.83 | 5.75 | 12.63 | 7.13 |
| EBIT | -- | 294.26 | -105.86 | -223.79 | -346.22 |
| Net Profit | -- | 206.42 | -22.05 | -217.31 | -308.23 |
| EPS | -- | -- | -- | -- | -- |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Aug-24 | Aug-23 | Aug-22 |
| EBIT-Margin
| -152.94 | -113.15 | -126.23 | -64.84 | -267.75 |
| Net Margin
| -- | -- | -- | -- | -- |
| Return on equity
| -64.75 | -44.84 | -81.23 | -38.17 | -74.85 |
| Return on Capital
| -49.49 | -34.68 | -65.98 | -28.25 | -54.24 |
| Return on Assets
| -40.56 | -29.07 | -47.64 | -24.62 | -49.41 |
| Debt to Equity (x)
| -- | -- | 0.32 | 0.18 | 0.45 |
Profitability
ROCE
-65.98
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Aug-24
|
Aug-23
|
Aug-22
|
Aug-21
|
Aug-20
|
|---|---|---|---|---|---|
|
Novo Integrated Sciences (NVOS)
|
-65.98
|
-28.25
|
-54.24
|
-9.74
|
-15.19
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-81.23
--
Profit after tax / Average Net worth * 100
|
Company Name
|
Aug-24
|
Aug-23
|
Aug-22
|
Aug-21
|
Aug-20
|
|---|---|---|---|---|---|
|
Novo Integrated Sciences (NVOS)
|
-81.23
|
-38.17
|
-74.85
|
-12.14
|
-17.81
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROA
-47.64
--
Profit after tax / Average Total assets * 100
|
Company Name
|
Aug-24
|
Aug-23
|
Aug-22
|
Aug-21
|
Aug-20
|
|---|---|---|---|---|---|
|
Novo Integrated Sciences (NVOS)
|
-47.64
|
-24.62
|
-49.41
|
-9.17
|
-14.53
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Margin
-126.23
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Aug-24
|
Aug-23
|
Aug-22
|
Aug-21
|
Aug-20
|
|---|---|---|---|---|---|
|
Novo Integrated Sciences (NVOS)
|
-126.23
|
-64.84
|
-267.75
|
-46.27
|
-60.65
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Margin
-121.32
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Aug-24
|
Aug-23
|
Aug-22
|
Aug-21
|
Aug-20
|
|---|---|---|---|---|---|
|
Novo Integrated Sciences (NVOS)
|
-121.32
|
-105.11
|
-281.52
|
-47.95
|
-62.53
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
0.06
--
Year on year growth in net sales
|
Company Name
|
Aug-24
|
Aug-23
|
Aug-22
|
Aug-21
|
Aug-20
|
|---|---|---|---|---|---|
|
Novo Integrated Sciences (NVOS)
|
0.06
|
0.07
|
0.26
|
0.18
|
-0.17
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Growth
-105.86
--
Year on year growth in operating profit (EBIT)
|
Company Name
|
Aug-24
|
Aug-23
|
Aug-22
|
Aug-21
|
Aug-20
|
|---|---|---|---|---|---|
|
Novo Integrated Sciences (NVOS)
|
-105.86
|
74.06
|
-629.89
|
9.68
|
-2,527.85
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Profit Growth
-22.05
--
Year on year growth in profit after tax
|
Company Name
|
Aug-24
|
Aug-23
|
Aug-22
|
Aug-21
|
Aug-20
|
|---|---|---|---|---|---|
|
Novo Integrated Sciences (NVOS)
|
-22.05
|
60.01
|
-640.57
|
9.22
|
-1,153.92
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.32
--
Total debt / Net worth
|
Company Name
|
Aug-24
|
Aug-23
|
Aug-22
|
Aug-21
|
Aug-20
|
|---|---|---|---|---|---|
|
Novo Integrated Sciences (NVOS)
|
0.32
|
0.18
|
0.45
|
0.31
|
0.15
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.21
--
(Short term borrowings / Net worth)
|
Company Name
|
Aug-24
|
Aug-23
|
Aug-22
|
Aug-21
|
Aug-20
|
|---|---|---|---|---|---|
|
Novo Integrated Sciences (NVOS)
|
0.21
|
0.11
|
0.17
|
0.13
|
0.04
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.37
--
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Aug-24
|
Aug-23
|
Aug-22
|
Aug-21
|
Aug-20
|
|---|---|---|---|---|---|
|
Novo Integrated Sciences (NVOS)
|
0.37
|
0.56
|
1.58
|
1.32
|
1.65
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Quick Ratio
0.30
--
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Aug-24
|
Aug-23
|
Aug-22
|
Aug-21
|
Aug-20
|
|---|---|---|---|---|---|
|
Novo Integrated Sciences (NVOS)
|
0.30
|
0.42
|
1.53
|
1.28
|
1.65
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Interest Coverage
-25.72
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Aug-24
|
Aug-23
|
Aug-22
|
Aug-21
|
Aug-20
|
|---|---|---|---|---|---|
|
Novo Integrated Sciences (NVOS)
|
-25.72
|
-1.59
|
-19.71
|
-26.10
|
-30.43
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
23.71
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
Aug-24
|
Aug-23
|
Aug-22
|
Aug-21
|
Aug-20
|
|---|---|---|---|---|---|
|
Novo Integrated Sciences (NVOS)
|
23.71
|
11.67
|
54.31
|
24.53
|
25.89
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Asset Turnover
0.39
--
Sales / Average Total Assets
|
Company Name
|
Aug-24
|
Aug-23
|
Aug-22
|
Aug-21
|
Aug-20
|
|---|---|---|---|---|---|
|
Novo Integrated Sciences (NVOS)
|
0.39
|
0.23
|
0.18
|
0.19
|
0.23
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Receivable days
63.46
--
Average Debtors / Sales * 365
|
Company Name
|
Aug-24
|
Aug-23
|
Aug-22
|
Aug-21
|
Aug-20
|
|---|---|---|---|---|---|
|
Novo Integrated Sciences (NVOS)
|
63.46
|
113.92
|
134.71
|
84.74
|
88.28
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
50.97
--
Average Inventory / Sales * 365
|
Company Name
|
Aug-24
|
Aug-23
|
Aug-22
|
Aug-21
|
Aug-20
|
|---|---|---|---|---|---|
|
Novo Integrated Sciences (NVOS)
|
50.97
|
41.99
|
25.91
|
11.31
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
163.23
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Aug-24
|
Aug-23
|
Aug-22
|
Aug-21
|
Aug-20
|
|---|---|---|---|---|---|
|
Novo Integrated Sciences (NVOS)
|
163.23
|
123.09
|
80.84
|
77.74
|
77.15
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
-48.80
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Aug-24
|
Aug-23
|
Aug-22
|
Aug-21
|
Aug-20
|
|---|---|---|---|---|---|
|
Novo Integrated Sciences (NVOS)
|
-48.80
|
32.82
|
79.77
|
18.31
|
11.13
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
EV/EBITDA
-0.38
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Aug-24
|
Aug-23
|
Aug-22
|
Aug-21
|
Aug-20
|
|---|---|---|---|---|---|
|
Novo Integrated Sciences (NVOS)
|
-0.38
|
-0.69
|
-0.25
|
-2.10
|
-0.84
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|